GILD vs VRTX
Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) compared side by side. Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $132.8B for Vertex Pharmaceuticals, about 1.5 times the size. GILD returned +32.4% over the past year including dividends, versus +24.0% for VRTX, through October 23, 2026..
Head to head
| Metric | GILD | VRTX |
|---|---|---|
| Market cap | $193.5B | $132.8B |
| P/E (TTM) | — | 29.9x |
| Forward P/E | 15.6x | 25.7x |
| Revenue (TTM) | $30.5B | $12.6B |
| Revenue growth | 10.2% | 12.5% |
| Gross margin | 79.6% | 55.0% |
| Operating margin | 33.7% | 38.1% |
| Free cash flow | $12.9B | $3.8B |
| Dividend yield | 2.10% | None |
| 1-year return | +32.4% | +24.0% |
| 5-year return (annual) | +22.6% | +23.3% |
| Max drawdown | -71% | -92% |
| FI Handbook grade | B- | B |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
$10.0K
$20.0K
$30.0K
20222023202420252026
GILD vs VRTX FAQ
Which is bigger, GILD or VRTX?
Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $132.8B for Vertex Pharmaceuticals, about 1.5 times the size.
Which stock performed better over the past year, GILD or VRTX?
GILD returned +32.4% over the past year including dividends, versus +24.0% for VRTX, through October 23, 2026.
Which pays a higher dividend, GILD or VRTX?
GILD yields 2.10%; VRTX does not pay a dividend.
Full pages: Gilead Sciences · Vertex Pharmaceuticals